News
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access Program, a molgramostim Expanded
ICON plc Schedules Third Quarter 2024 Earnings Conference Call
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the
EQS-News: Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is
EQS-News: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
LivaNova to Announce Third-Quarter 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time
Humana and Interwell Health Announce Addition of State of Florida to Value-based Kidney Care Program
Leading health and well-being company Humana Inc. (NYSE: HUM), and kidney care management company Interwell Health, have expanded their value-based care agreement to include Florida for eligible
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Savara to Host Analyst and Investor Webinar on September 30, 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 from
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
Texas A&M University Mays Business School and Humana Launch Annual Nationwide Healthcare Analytics Case Competition
Mays Business School at Texas A&M University and leading health and well-being company Humana Inc. have kicked off the 2024 Humana-Mays Healthcare Analytics Case Competition. The competition – in
Humana Earns 2024 Great Place To Work Certification
For the third consecutive year, Humana Inc., a leading health and well-being company, is named a Certified™ Great Place To Work®. The prestigious award is based entirely on current employees'
Agilent Announces Cash Dividend of 23.6 Cents per Share
Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, October 29, 2024. The
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, October 29, 2024. The
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination